HBV特异性T细胞作为生物标志物，用于中止慢性乙型肝炎的核

StephenW

Hepatology. 2018 Aug 31. doi: 10.1002/hep.30243. [Epub ahead of print]
HBV-specific T cells as a Biomarker for Discontinuation of Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B.
Tian Y1, Ou JJ2.
Author information

1
    Department of Pathology and Laboratory Medicine, Los Angeles County and University of Southern California Medical Center, Los Angeles, California.
2
    Department of Molecular Microbiology and Immunology, University of Southern California Keck School of Medicine, Los Angeles, California.

Abstract

Hepatitis B virus (HBV) can cause severe liver diseases and is a major health problem. It chronically infects approximately 250 million people worldwide. Nucleos(t)ide analogs (NUCs), including lamivudine, adefovir, entecavir, tenofovir and telbivudine, are the most frequently used drugs for treating chronic hepatitis B (CHB) patients. NUCs can efficiently suppress HBV DNA replication and reduce viral load, leading to the loss of the HBV e antigen (HBeAg), the appearance of antibodies against HBeAg, and the normalization of the alanine aminotransferase (ALT) level. However, they cannot target the HBV genomic DNA, also known as the covalently closed circular DNA (cccDNA), in infected hepatocytes. For that reason, the discontinuation of the NUC therapy can lead to viral rebound and the development of hepatic flares, and a lifelong treatment of this therapy is often required for CHB patients. Nevertheless, there are also some patients for whom the treatment with NUCs can be safely stopped. Unfortunately, the biomarkers for the identification of this subset of patients are currently lacking. Recently, Rivino et al. found that the population of PD1+ HBV-specific T cells was much higher in chronic HBV patients who successfully discontinued the NUC therapy without developing hepatic flares than in those patients who developed hepatic flares (1). Their finding indicated that PD1+ HBV-specific T cells might serve as the much-needed biomarker for safe discontinuation of the NUC therapy for CHB patients. This article is protected by copyright. All rights reserved.
KEYWORDS:

HBV ; HBV-specific T cells; antiviral therapy; biomarkers; nucleos(t)ide analogues

PMID:
    30168616
DOI:
    10.1002/hep.30243

StephenW

肝病。 2018年8月31日。土井：10.1002 / hep.30243。 [提前打印]
HBV特异性T细胞作为生物标志物，用于中止慢性乙型肝炎的核（t）类似物治疗。
田玉1，欧JJ2。
作者信息

1
    洛杉矶县病理学和检验医学系和加利福尼亚州洛杉矶南加州大学医学中心。
2
    南加州大学凯克医学院分子微生物学和免疫学系，加利福尼亚州洛杉矶分校。

抽象

乙型肝炎病毒（HBV）可引起严重的肝脏疾病，是一个主要的健康问题。它长期感染全球约2.5亿人。 Nucleos（t）ide类似物（NUCs），包括拉米夫定，阿德福韦，恩替卡韦，替诺福韦和替比夫定，是治疗慢性乙型肝炎（CHB）患者最常用的药物。 NUC可有效抑制HBV DNA复制并降低病毒载量，导致HBV e抗原（HBeAg）的丢失，抗HBeAg抗体的出现以及丙氨酸氨基转移酶（ALT）水平的正常化。然而，它们不能靶向感染的肝细胞中的HBV基因组DNA，也称为共价闭合环状DNA（cccDNA）。因此，NUC治疗的中止可导致病毒反弹和肝脏发作，并且CHB患者经常需要终生治疗该疗法。然而，也有一些患者可以安全地停止使用NUC治疗。不幸的是，目前缺乏用于鉴定该患者子集的生物标志物。最近，Rivino等人。研究发现，慢性HBV患者PD1 + HBV特异性T细胞的数量明显高于成功停用NUC治疗而未发生肝脏发作的患者，而非发生肝脏发作的患者（1）。他们的发现表明，PD1 + HBV特异性T细胞可能是安全停止CHB患者NUC治疗的急需生物标志物。本文受版权保护。版权所有。
关键词：

HBV; HBV特异性T细胞;抗病毒治疗;生物标志物;核苷（酸）类似物

结论：
    30168616
DOI：
    10.1002 / hep.30243